Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing material definitive agreements related to its corporate headquarters and laboratory space. The company, through its subsidiary Old Saw Mill Holdings LLC, has extended a $720.0 million lease financing agreement for its New York-based facilities. This extension spans five years, moving the maturity date from March 2022 to March 2027. The amended agreements involve a restated participation agreement and a restated lease, which govern the financing and the company's use of the property. These extensions provide continued operational stability and maintain the existing financing structure for these critical assets. The terms include variable interest rates based on SOFR plus a spread and margin, and Regeneron continues to operate under a triple-net lease structure for the facility. The company retains options for further extension or a potential purchase of the facility at maturity.
Key Highlights
- 1Regeneron extended its $720.0 million lease financing for its corporate headquarters and laboratory facilities by five years, now maturing in March 2027.
- 2The extension was executed through Second Amended and Restated Participation and Lease Agreements.
- 3The lease remains a triple-net lease, with Regeneron responsible for maintenance, insurance, and taxes, partially offset by subleasing income.
- 4The financing costs are tied to a variable rate based on SOFR, plus a spread adjustment and an applicable margin.
- 5Regeneron and certain subsidiaries have provided a restated guaranty for the lessee's obligations.
- 6The company has options to further extend the lease for an additional five years or to purchase the facility at maturity.
- 7The amended agreements include financial covenants such as maximum total leverage ratio and minimum interest expense coverage ratio, similar to existing credit facilities.